PMS2

Across TCGA pan-cancer cohorts, PMS2 mass-spec protein differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of PMS2’s most consistent transcriptional readouts.

The strongest signal is observed in lung adenocarcinoma (LUAD), where PMS2 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types PMS2 is over-expressed in tumor, although a few such as CCRCC and PDAC show the opposite, repressed pattern.

LUAD, CCRCC, and HNSC are the cancer types where PMS2 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in PMS2 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LUAD	All	III,IV	+0.353	<.001	9	view →
CCRCC	All	III,IV	−0.120	<.001	9	view →
HNSC	All	IV	+0.273	<.001	8	view →
PDAC	Male	All	−0.220	.002	5	view →
COAD	All	III,IV	+0.438	.048	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

PMS2–LUAD

Open the LUAD breakdown →